Study Demonstrates Feasibility and Tolerability of 45 Gy Novel Radiotherapy in CNS Cancers
October 25th 2022In an interview with Targeted Oncology, Rupesh Kotecha, MD, discussed research around the use of pulse reduced dose rate intensity-modulated radiotherapy in patients with central nervous system malignancies.
Read More
Wearable Patient-Tracking Device to Inform Time and Delivery of Radiotherapy
October 22nd 2022Alonso Gutierrez, MD, discusses the initial results from a feasibility study which evaluated the use of a daily wearable patient-tracking device to optimize radiation machine use and time the delivery of treatment.
Read More
Study Shows H-RT Is Safe, Effective for Low-Risk Prostate Cancer
October 21st 2016Study results that examined patient-reported outcomes and quality of life measures demonstrate that hypofractionated radiotherapy (H-RT) is a viable, safe, and value-added alternative to patients with low-risk prostate cancer.
Read More
Findings of a Study Comparing Standard Radiation to IMRT in Endometrial, Cervical Cancer
October 19th 2016Ann H. Klopp, MD, PhD, discusses the results of a recent trial comparing standard radiation to intensity-modulated radiation therapy (IMRT) in endometrial and cervical cancer, and what impact these results will have.
Read More
Computer Simulation Helps Plan Transducer Placement in Glioblastoma
October 14th 2016For patients who are likely to experience contiguous recurrence of glioblastoma, a new computer simulation using tumor treating fields (TTF) and employing a personalized transducer array, delivered electric field (EF) intensities that exceeded therapeutic intensities in 3 different tumor locations.
Read More
High Rates of Overall Survival Show Benefit of SBRT in Unresectable Liver Cancer
October 14th 2016Results from a phase II study from Korea demonstrated high rates of tumor local control, overall survival (OS), and grade 1/2 gastrointestinal and hepatic toxicities in patients who received stereotactic body radiotherapy (SBRT) for unresectable hepatocellular carcinoma (HCC) after incomplete transarterial chemoembolization (TACE).
Read More
Radiation-TGFβ Inhibition Combo Elicits Activity in Metastatic Breast Cancer
October 14th 2016A strategy to stimulate an immune response in radiation-damaged tumor cells resulted in preliminary evidence of activity—including longer survival—in a small clinical trial of patients with metastatic breast cancer.
Read More
KRAS-Variant HNSCC Outcomes May Improve With Cetuximab
October 13th 2016Patients with head and neck cancer whose disease is associated with <em>KRAS</em> variant had significantly better progression-free survival (PFS) and overall survival (OS) when treated with the monoclonal antibody cetuximab (Erbitux), according to findings of a retrospective analysis of a randomized trial.
Read More
No Benefit from Combined Irradiation in Intermediate-Risk Prostate Cancer
October 7th 2016The addition of external-beam radiotherapy (EBRT) to interstitial brachytherapy failed to reduce prostate cancer progression compared to brachytherapy alone in men with intermediate-risk disease, interim data from a randomized trial showed.
Read More
Study Results Show Chemoradiation Significantly Improves PFS in Follicular Lymphoma
October 1st 2016According to findings from a multicenter randomized trial, chemoradiation for early-stage, low-grade follicular lymphoma led to significant improvement in progression-free survival (PFS) compared with involved-field radiotherapy alone (IFRT).
Read More
Long-Term Study Reports RT Plus Anti-Androgen Improves Prostate Cancer Survival
October 23rd 2015Patients who had prostate cancer recurrence after radical prostatectomy lived significantly longer with the addition of hormonal therapy to salvage radiotherapy, long-term follow-up from a randomized trial showed.
Read More
Trend Toward Less Bowel Toxicity for IMRT Versus 3-D Conformal RT in Cervical Cancer
October 23rd 2015Intensity-modulated radiation therapy (IMRT) for cervical cancer has led to a double-digit decrease in late bowel toxicity compared with 3-D conformal radiation therapy without statistical significance.
Read More
Brief RT for Early Prostate Cancer Gets High Marks in Preliminary Trial
October 22nd 2015Ultra-hypofractionated radiation therapy for low-risk prostate cancer led to significantly lower rates of bowel and urinary dysfunction compared with patients treated with conventional radiotherapy regimens.
Read More
Prostate Cancer Study Shows Hypofractionation Comparable to Standard Radiation in Low-risk Patients
October 21st 2015Hypofractionated radiotherapy can achieve similar cure rates with similar side effects compared with conventional radiotherapy for men with low-risk, early prostate cancer, according to a recent study.
Read More
Dr. Jay Ciezki Talks About the Benefits of Stereotactic Body Radiation Therapy
October 20th 2015Jay Ciezki, MD, staff member of the Department of Radiation Oncology at Cleveland Clinic and Department of Cell Biology at Cleveland Clinic, talks about the potential advantages of utilizing Stereotactic Body Radiation Therapy in prostate cancer patients.
Read More
Coordination of Care Based on Patient-Reported Outcomes Improves End-of-Life Care and Lowers Costs
October 19th 2015Coordinating radiation therapy teams and palliative care teams based on patient reported outcomes from University of Virginia Health System improved outpatient symptom management and decreased end-of-life hospitalizations, as well as costs of care for patients with late-stage cancer.
Read More
Low-Risk Stage IV NSCLC Patients Achieve Long-Term Survival After Aggressive Treatment
September 17th 2014Timing of metastatic development, lymph node involvement, and type of disease all factor into the overall survival (OS) rate of patients with stage IV NSCLC, and could offer a potential risk stratification scheme for ablative therapy.
Read More
Chemo/SABR Combo May Allow Patients With Advanced Pancreatic Cancer to Undergo Surgery
September 17th 2014The combination of chemotherapy and stereotactic ablative radiotherapy (SABR) may allow patients with locally advanced pancreatic cancer to undergo surgery, a procedure that might not have otherwise been an option.
Read More
MRI-Guided Radiotherapy Reduces Sexual Dysfunction in Prostate Cancer
September 17th 2014With the use of MRI imaging to restrict doses to erectile tissues, nearly half of men treated with EBRT for prostate cancer were able to be sexually active without aids or medications 5 years later, and nearly 80% could be sexually active if such support was an option.
Read More
Abbreviated Course of ADT + RT Produces Similar Outcomes, Improves QoL in High-Risk Prostate Cancer
September 17th 2014When given along with radiation therapy to men with high-risk prostate cancer, 18 months of androgen-deprivation therapy (ADT)—as opposed to a 36-month course—not only generates similar long-term outcomes, but results in a better quality of life.
Read More